Global Uveitis Treatment Research Report 2024: Market to Reach $1.34 Billion by 2034, Fueled by Increased Prevalence, Treatment Improvements, and Strategic Alliances & Collaborations
May 16, 2024 10:30 ET
|
Research and Markets
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Global Uveitis Treatment Market" report has been added to ResearchAndMarkets.com's offering.The global uveitis treatment market accounted for USD 753...
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 16:05 ET
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected Q3 2024 - - Strengthened Management Team and Board of Directors with Two Key Additions -- Management to Host Webcast...
Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference
May 08, 2024 16:15 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 12, 2024 16:05 ET
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner Programs Continue to Report Positive Clinical Data Utilizing SCS Microinjector® - - Strengthened...
Global Macular Degeneration Treatment Market Forecast to 2031: Breakthrough in Durable Anti-VEGF Drugs Redefines Patient Care with Less Frequent Dosing
January 26, 2024 06:27 ET
|
Research and Markets
Dublin, Jan. 26, 2024 (GLOBE NEWSWIRE) -- The "Macular Degeneration Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade,...
Retinal Biologics Global Market Report 2023: Innovations Key to Future Advances - Long-term Forecasts to 2028 and 2033
January 25, 2024 09:33 ET
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Retinal Biologics Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. Profound analytics indicate that the...
Retinopathy of Prematurity Research Reveals Market Insights, Epidemiology, and Forecast to 2032
January 24, 2024 10:49 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Retinopathy of Prematurity - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. ...
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023 16:05 ET
|
Clearside Biomedical, Inc.
- New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside’s Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor - - BioCryst Collaboration Provides $5...
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference
November 08, 2023 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD
November 01, 2023 07:05 ET
|
Clearside Biomedical, Inc.
- Successful Completion of Recruitment Driven by Strong Clinical Site Participation and Investigator Support - - Topline Data Expected in Q3 2024 - ALPHARETTA, Ga., Nov. 01, 2023 ...